-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 STfxVzc/vHHMQVBb3pU85F1QYQdbsAAGsNqbtLhhkKBD5yQF1VbU2mmEr9fRGLaz
 Eh9hElzaGWfPUQGNL6FF5Q==

<SEC-DOCUMENT>0000950144-07-006322.txt : 20070703
<SEC-HEADER>0000950144-07-006322.hdr.sgml : 20070703
<ACCEPTANCE-DATETIME>20070703113720
ACCESSION NUMBER:		0000950144-07-006322
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070703
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070703
DATE AS OF CHANGE:		20070703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER & OFFICE EQUIPMENT [3570]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		07958465

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g08214e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt; margin-top: 6pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>Securities Exchange Act of 1934</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): July&nbsp;3, 2007</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in Charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Illinois<BR>
(State or other jurisdiction of <BR>
incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091<BR>
(Commission<BR>
File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038<BR>
(IRS Employee<BR>
Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1256 Briarcliff Road N.E.<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
(Address of Principal Executive Offices)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(404)&nbsp;727-0971<BR>
(Issuer Telephone number)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Registrant under any of the following provisions (see General
Instruction A.2 below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule&nbsp;13e-4<SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> under the Exchange Act (17 CFR 240.13(e)-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time
to time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 Other Events</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;3, 2007 we issued a press release related to the engagement of BioReliance Corporation
as contract manufacturer for our HIV-1 MVA (Modified Vaccinia) (AIDS)&nbsp;vaccine. A copy of the press
release is attached to this Current Report.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99 Press Release
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dated: July&nbsp;3, 2007</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<P align="right" style="font-size: 10pt"><!-- Folio -->2 of 5<!-- /Folio -->

</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>g08214exv99.htm
<DESCRIPTION>EX-99 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;99</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g08214g0821400.gif" alt="(GEOVAX LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>AT THE COMPANY</U></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Donald Hildebrand / Jennifer Nelms<BR>(404)&nbsp;727-0971</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FOR IMMEDIATE RELEASE<BR>29 JUNE 2007</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">GeoVax Producing MVA-AIDS VACCINE for Phase 2 Human Trials
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ATLANTA, Ga. &#151; 3 July&nbsp;2007 &#151; GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based
biotechnology company, announced it has engaged BioReliance Corporation as contract manufacturer
for its HIV-1 MVA (Modified Vaccinia) vaccine. This AIDS vaccine will be used in GeoVax&#146;s Phase 2
trials planned for early 2008.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax HIV-1 MVA vaccine, manufactured by BioReliance in its Glasgow, UK facility, is the second
part of a two-vaccine &#147;Prime and Boost&#148; immunization regimen intended to stimulate protection
against development of AIDS in humans. GeoVax&#146;s vaccination program utilizes 2 AIDS vaccines with
the 1<SUP style="font-size: 85%; vertical-align: text-top">ST</SUP> being a DNA vaccine designed to prime a person&#146;s immune response and the
2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> a MVA vaccine administered to boost the an anti-HIV-1 immune response. Both vaccines
express the 3 major proteins of the AIDS virus &#091;HIV-1&#093; with no risk of causing AIDS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s human trials began in April&nbsp;2003 to evaluate safety and efficacy of both its DNA &#038; MVA
anti-HIV &#091;AIDS&#093; vaccines. To date, one trial has successfully concluded, 2 are ongoing since 2006,
and 2 additional trials are slated to begin July&nbsp;2007. Encouraging safety and immunological
results from these Phase 1 trials support the acceleration of GeoVax&#146;s Phase 2 clinical studies
which are in the planning stage for an early 2008 start.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Summary of Ongoing Human Trial Results:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Data from 2 current human trials indicates GeoVax&#146;s HIV/AIDS vaccines:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Demonstrate very acceptable safety profiles in both the 1/10th dose trial begun Apr06
and full dose trial begun in Sep06.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Stimulate potentially protective anti-HIV immune responses in 100% of vaccine recipients
in people receiving only 1/10th of a dose in each of 4 vaccinations.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Early data from a Sept 06 trial where individuals received 4 full doses of our AIDS
vaccine indicates the vaccine is stimulating promising levels of anti-AIDS immune responses
with the final data to be released at a later date.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax chose BioReliance as the contract manufacturer for its MVA vaccine based on their successful
experience manufacturing Vaccinia-based vaccines and excellent regulatory history.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cyndi Tolman, Vice President of GeoVax Labs, Inc. commented, &#147;We are very pleased with our decision
to utilize BioReliance as contract manufacturer for our MVA vaccines. Manufacturing of additional
vaccine for our Phase 2 human trials is an important step</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->3 of 5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">forward for our AIDS vaccine development plan and demonstrates our confidence in the success of our
AIDS vaccine program.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Human trials, utilizing GeoVax&#146;s AIDS vaccines, are being conducted by the HIV Vaccine Trials
Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, which is funded and supported by the
National Institutes of Health (NIH), is the largest worldwide clinical trials program devoted to
the development and testing of HIV/AIDS vaccines. Preclinical work enabling development of the
clinical evaluation of GeoVax&#146;s DNA and MVA vaccines was also funded and supported by the NIH and
National Institute of Allergy and Infectious Diseases.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">****************************************
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">About GeoVax Labs, Inc. <I>(www.geovax.com)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, license and
commercialize the manufacture and sale of human vaccines for diseases caused by HIV-1 &#091;Human
Immunodeficiency Virus&#093; and other infectious agents. HIV/AIDS vaccine technology is protected by 20
issued and filed patent applications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s DNA and Recombinant MVA vaccines:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Protected 22/23 &#091;96%&#093; non-human primates for over 3<FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> years post-infection with an AIDS
causing virus &#151; 5 of 6 non-vaccinated controls died of AIDS</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Satisfactorily manufactured and tested under GMP/GLP &#151; EMEA &#038; FDA guidelines</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Satisfactory completed Phase I human clinical trials</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Currently in 2 ongoing human trials with positive immune responses reported in the
majority of vaccine recipients as well as good vaccine safety. Two additional Phase 1/2 stage
human trials with GeoVax AIDS vaccines started in June&nbsp;2007 with a Phase 2 trial planned for
early 2008.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">About BioReliance Corporation <I>(www.bioreliance.com)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BioReliance Corporation is a leading contract services organization, offering more than 1,000 tests
or services related to biologics safety testing, in vitro and in vivo toxicology, viral
manufacturing and lab animal health diagnostics for the biopharmaceutical and pharmaceutical
industries. The company provides cost-effective services to over 600 clients annually, including
most of the largest pharmaceutical and biopharmaceutical companies in the world. BioReliance has
its primary facilities in Rockville, Maryland; Glasgow, Scotland; and Stirling, Scotland.
Headquartered in Rockville, Maryland, BioReliance employs over 700 people globally.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Safe Harbor Statement</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>All statements in this news release that are not statements of historical fact are forward-looking
statements. These statements are based on expectations and assumptions as of the date of this
press release and are subject to numerous risks and uncertainties which could cause actual results
to differ materially from those described in the forward-looking statements. Risks and
uncertainties include, but are not limited to, whether; GeoVax can develop these vaccines with the
desired characteristics in a timely manner, GeoVax&#146;s vaccines will be determined to be safe for use
in humans, GeoVax&#146;s vaccines</I></DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->4 of 5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals
necessary to be licensed and marketed, GeoVax can raise the required capital to complete
development of its vaccines, there is development of competitive products that may be more
effective or easier to use than GeoVax&#146;s products, and other factors over which GeoVax has no
control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. Certain matters discussed in this news release are forward looking statements
involving certain risks and uncertainties including, without limitations, risks detailed in the
Companies Securities and Exchange Commission filings and reports.</I>
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->5 of 5<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g08214g0821400.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g08214g0821400.gif
M1TE&.#EA2P$S`.8``.[M\?'Q]922J1@40K*PP='0VJ*@M.+AZ<&_R^#?YE51
M=-S:XRHE4F1A@(2"G49":2<B371QCM#.V75SD>#@YP<",S8R6H.`F,W+V#@U
M79*0ILK(U@@#-<;$T4A%:YV;K]+1W$5!9&UIC,'`S3LW86)>?5E5>Z6CN593
M>(6#H-;5W^KI[H.`FJNHNL'`SGAUDL+!SL3#T<+!T%%-<FEFA<7$U#$L5LC'
MU%U9>W%MBV5B@Z*@LDU)<XB%HVEFB:BFN[2RQ*.BMI>5K+6TQ=32W>3BZ=C7
MX45!9H.!FF9CA=74X)N8KZ"=LPX).X:#GL/"SPL&.>;EZT9"9\#`RJVKOWYZ
ME1810$U);O;U^!(-/8Z+JN_O\UY9@+BVQHB&GQ\:2/7T]Z:DMN?F[(*`E\3"
MSUE6=X)^FT`\8XV+HD5"9\+!S9&.IFMGAK.QPK.RQ&1??D1!8F=EB`P'-P8"
M+X.!F[&PP/#P]//S]NCG[45"96=C@WMXFOCW^>SJ[P<",?___R'Y!```````
M+`````!+`3,```?_@'^"@X2%AH>(B8J+C(V.B@D-7Y,Y`(^7F)F:FYR=GI^@
MH:*CG@X5?GX/":2LK:ZOL+&RLZ-IJ!4%M+J[O+V^NG=*-0C$Q<;'Q3$28IH)
MIWX>O]+3U-6T`!W$'QYP(2$,IW.HX^3EYN>HXE_>(0\OQ:N#$^,PUO;W^/F$
M"Q<7.-X,T`D<2+#@N3D,[`Q`Q6#$"7T0(TH<!0,!FC$S0@P09W#@G(]0K%A@
MYPU.-Y(G25K(PN$C00$GQ@5YX&<.!Q(YD+1`<&>BSY\^`R!H,Z9,"`X=RWU<
M%\+#A`MCD!@P5D-"`$T!,,@PQH3%F`L1'IQIDL5%0#]6MEA!E^'("P$(_U0`
MG4N75Q$"8VQP3#JG@HT09;Y*R)=@'(T"WYX-K)`#;L^ZD"-W4N&%A)RDJ`8`
M1M`!*!U4'-P4>H(@XV6!"/5TELRZ]:$J4II@MG&!"IG("9#Z2</HR8\+5_8J
M):&GA>OC<[<,B9!!N$`Y(2((47/<P#@#F-2$F1!"CO,Y`Q1\H("\/#X$2"PH
M1LU`CY#5R+<<004EGJ8.+2*0<.X'0H,P49@G8"\'&#!?07)(,08S`_Y1QSA.
MB.*%`@LIE8-]#69(BATTK(?.'"0$<=4B(*`1PA=9I$B2-R*\@@`$'\GQPR4*
M@)8+*2#0<1HY#`RAX8^?)$!300SL,.(B+U18D/\`L$!QRXV-5&@!+&KHH-LX
M7[P`Y):7%-#`6@,-,,$3CA@``687P&+`,T$XTL`M!,A2H!3K2=$FEW@BH@&8
M`@V@@Q*/1,`G0R&8M&((&33Q!BP)G-D?>8PX"L$N8=`Y#@<-;)'GIG]LX0%!
M'*``J2,1D`-!%7@L4H0>L5PP3IJ+C#!.`[W`8`$Y4$#)Z8\4A$#0`!@V,@]H
M7-PCP3,6:*K(K7YP((T7?'*`W:X_GB60"9G(>HN6^`Q9@0:0/*/#-$1(,8X5
MTU([(+/H6''G)5NPRV0^+CSS@"(:W/+N+UN\B8H5=:@KX(,"2:N)$\\P$%&%
M%<B`R!:.AJ#L-%O4B`K_!$4(7)ZCZ,RHB;]^9!P*&0*PX$1<C1"!Q%<7,$%(
M"N/$@8AUJ,PKR`@"]",`F5OT<T'`!3CALP$3$Y*`SQ?0\=@B'#N@,7(#3;F)
M;@.`L@4-5XX#01N)$&"!<TTXH6R%'!0]B,45V"%($EEGYH.WFE(PI!\1&++%
ME0^8G4ANJ&3P]'$#U:-)#\]@ZXD,@Y93032&6(P.!"[\$<<X/1A"LQ](_'$`
MQ^?H5D$\?*-"0R$\C,-`L(N4VNS?KA7,R6>HH/Y'$$C7?@$2$R/`YP!'T#`#
MNW[X3<B!-5E00@Y'7&G%$Q0XZ<<`:A,",@4%L#N`!_UXD'@%A+2A&P=."T)P
M__`'8+)F\*RWEOBEG#@!VB$$M&V.`H(40+8)@`JRA1-*CBL($N,8@!>.U`;U
M9&8+20!-#`H!IDE]"A4*$,T@;$4.[A'"!,^PP@)!P*P*".X2"#A%$M+'&A^@
MPUF;<-_J#&&+@I#I@17@`2(<Y<$_4""#B"`!Y>R'BG3]85A^`($,D(6(+XSC
M<X7(@-;LX#@?/F)-')`="8&R/E3HZA(.&$<7#$&\@8S@6*A`02($H!LZ_"&+
M?O@6(GCH!P800745F%B%K/`'1PU`;_7S7.0(L;EQV&`<]-/$`RH@QBE*)@$[
M(H?,!O<,&1:B`50X1`#T,(X1T*P"(U#$@2;EKR,H8O]\$M"6'^Y4@''4[1D3
M4(02T[A'0A2`<_W!(R."4`'#&5(R08`E*FZCB0I5K1`+2(2K4#$"`#8+0ULP
M`-)HV"A4A`\1+M"-TP[T`+6MT@I%&,$I*O#,0Z`1B89X@F(XP+5,(,X'LKPE
M4%YI#@9<T1&4C-TCANF'8KZ/$!/PT"VTB8H()0(&NF&!@T`#!`KHAG[:JL"^
M#,&"6[2R$%?Z)2:",``!I%.=<W&<Z0:#"0$\`PKSK"3L.%"^09CK'%*@@*-@
MA8@0.E,0%=*!ORJ`G81Z01'#!&<A+H<*6S9B"RE@@,@P>AQVDF,`<L%$"_W@
M`T?0<P1`J"0A?&6.Y?T!!:C_H%4BQK='FEG!7IK:`BH5X2V.$@(&2AJ'CQPA
M`BT0=4`CR%H%N/4(9]RBJ8QX*@)TXU,.^-.;_]H!(A*P2@Y$;POF*.<?F`4L
M1!S@B&8=!+M>H!@G'F(!&WAKA@)0!P4H)@.*;40$%-.`42'BJ7]HH17^*D5!
M@.`9$(CLV<9!US_H@$<3XZ<?2("Z+2A)IX+`*BI2J8=GX$*S3PM"`YQGA3)L
MT1'&O)@70"!,J8Z`3PJXZ&PSLP17.LX*&((!.6J[6*VM]68:M>`@1)FL3A'/
M`K*]@19*BEP\.4`*2)F##9[+""^88PY-L(*`!VR%'7$T7^2X@NWZ,08@2+8<
M;+B`_Q'/A;H#`?</"0`>;2Z0R%M,3*S_RJ0@$G!2/Z`@8R!H@0A$P*!.N0!#
M!4"`;.OZLU'$F!@N.%(F*'`!$6^B`"Y05@(00*99C&$.(6!%`(00G&;AH!$@
M6&I'?-P&?:(C7<)]G.SRV<9#>&H@4-BF61W%@8<0`F+D`)]I;S8'_\&T`GO8
M1`(MRPF7TD>[BOB,&3FQD+6FH`(DH(5_!6L@5HTB`$MX@0>:D`$D="%ZB.AL
M6@?B0Q#H0)?F0`&D"="<<D``"?0M1`&^^DY!!$``L$2(`)I)MRU0$()Z\UX6
M%/`#63K#DX+(9S2P,`(R]$%5,1BJ(6X03$(80;9]6'.G./]@A8<8P:V"N,,-
MP&"(&!#A$1LHMB#X@`%A$\*@'+CV'Q(XND6L8-I_N$,'5D`(#,C8$"O8P*\-
M42HWL^(&:U``"4A``R#HN!`@$,(%V%""@AO\X"4P@Q$*D0`'7`#A"'\#`?@P
MB``0A>!C&,\B-,"&120@##0HP1O8$(:2NB$'!5\#R@M>!2G"8`-86$0%K'`C
M",0V`6=HUAD6^(<1-,`;::!``@3``"@P(`5;2$,($@"#$#1``4WX0CG;\(`O
M6`$%N2B`#FP``0^8]EA6'00"$T4",WO@"":`PA?24#<,AR!S1W@`!1`0`A_H
MH0D6</`?@#"#+#!``%+`]2!<X`?_D`H"')4+?-S2X$D#A&`"-FC"%2AP!2B<
M88\OR`):YJ6!$`A@+&?0E`1"<(0$A&`M$#C"ST7\``7P7!0_4/0+6O#!^C*"
M`YB<G1_`%80X"`$%N/^#&RK``0O@X`INH$D34#"#DZW.?7X/R*1HV00AY`!]
MX.""$!YP1:1`H46":$`%N+"$+W"@"'?C`!0>7WQ!W&HJA3^C'YK`@#,Y:P1G
MRH`"6J(P0@B@\#X#`0,``K(R*7_P!-!@6X5'`J?``1FP%HS#`ST05'X0)R@`
M8`^P$&:T)A"@`CA0`7.``R7@*YGC#(74"EN``4S`!3-@!AA@>\O"`4,@`59@
M6(*P`%/0_P80P#TUF`+RX`=?0`ANX`?C4B.!%B_<<P05L&<6,"5(L6>&<`)@
M$FADQ!M_0`<50`$Q4`$5$#!_$'_603_YDCE8Y3=(F%HFYGY^X$B#D$4?X1*\
M(5[^\W_@HH0R0Q-3<@`<8(5_D`UOX@!Q50$S0@"+<X450#^Y(3RC)3:W4FJM
M@`42,&,P*`B#1`<TX309YA(5<"\58`&05BJI-`@`A!UI4#9_`%`@U45^D&0G
M@!1?X#!V@U4<``/T1!]_@`!^$(I_4'1_4(,.]AG8H82:`E#<4XIZAU5M)PC-
M4P$U<#-T\P?Y,BU_E`"-8H`UXC3^%0V"(@ZR,0)/T'[RER;SL?^!%8!K/1`J
M^7(ODU@-^90&%7!'C5(!+N-11V`'%0`!4%(C]H847_15XN,'4\*%4S"04\!1
M;H!5?%@(8L4!,?``'.`#!#D%?_`F[S)(E%1(7.@"VF2`\7,O^%4/6\``H4$(
M(,`!-O@')N`'/D@3D?-:90-05KB#E.@'=&`=,W``N9&%9.0_KH(=7T4>**!&
MFL,!$-`$'*!LZ]@+6,B%0O`']L,!!3`$ZC%""Y$!Q'``+#!S0A`$!N`,9;,F
M4@-`$;*#!F`'3W`#?Z`":/D"?B!X?V`$%Q`&0$`#SW,`^?0`-7``71`@C3@(
M.E`!4``%Y%$`4%`VM!1(^:(ER6,"&##_2%8064(P?X-@1`]!$RA@`#3A+/G2
M=A4@/`/0A5FD!P?PE\Z20/[D6:O``;\T2!$@.!"`>[J8E-)`2^@C"*IC='-0
M/CW`,".0`,2#`@3P/'\`0.%3(X,Q!-9"/W]4$QS@8W_@/:"!,3:D0Z`1.29)
M"`CC!^!7!W,P*>[C@W^0!W.0.3\@&^I7B(0`0.5F!X5)71[5+%`P!]I8`9%4
M+YZ$6`-0``7P#";I2;Z"`&]V1A609+:%%/TW'P,0:K)Y#Z11!`?0C()@!T1@
M!"\H"-F&`7?PH/F3"%N@`@N@`NSV!QC0!TH`:8-`&@CP>LJX`"`0((V@H88@
M`0@0#T4@`1A`3DD^Q0A$@``'\*#B=@AV4`/YXVHW4`3OY@A&<`/Y<RLVLZ!.
M*@H1@`(.\)<50%T^404!$4A/NJ6@8`(9(`<V<`7P(1$_(`=-P`,_*@B!```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
